Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: Pooled analysis of 13 interventional clinical trials
B-cell levels and placental transfer in infants potentially exposed to ocrelizumab during pregnancy: Primary analysis of the prospective multicentre, open-label phase IV MINORE study
B-cell levels and breastmilk transfer in infants of lactating women with multiple sclerosis treated with ocrelizumab: Primary results of the prospective, multicentre, open-label, phase IV study SOPRANINO
COVID-19, coronavirus disease 2019; ECTRIMS, European Committee for Treatment and Research in MS; IRR, infusion-related reaction; OLE, open-label extension.
Prescribing information
Indications vary in different countries. The local prescribing information from your country is the primary source of information on the known and potential risks associated with ocrelizumab.
Archived data reports for fatalities were last updated February 2021. Please note that there will be no further updates of these archived materials
M-XX-00019243 (Date of preparation: December 2024)